Summary:
dreaMM3: A clinical trial for patients with relapsed/refractory multiple myeloma
Multiple myeloma (MM) is a rare and currently incurable cancer. Although there have been significant advances made in treatment, many MM patients still relapse or develop treatment resistance. There is an urgent need to develop new treatments that work differently.
Why is the dreaMM3 study being done?
The dreaMM3 study is comparing a single study drug (belantamab mafodotin, which has recently been FDA-approved but is not currently being distributed to patients outside this trial) to an approved combination therapy for treatment of relapsed/refractory multiple myeloma (RRMM). The study will examine the study drug’s ability to prevent cancer from getting worse.
Is the dreaMM3 study an option for you?
The dreaMM3 study might be an option for you if:
- You are at least 18 years old (the minimum age may be higher in some countries)
- You are diagnosed with multiple myeloma
- You have been previously treated with at least two anti-cancer drugs
- You have had an autologous stem cell transplant (SCT) or been told by your doctor that you cannot have one
- Your cancer has gotten worse since your last treatment ended
There are other eligibility requirements that the study doctor will review with you.